← All themes
Biotech (new drugs) stocks
바이오 신약
What are Biotech (new drugs) stocks in Korea?
The Biotech (new drugs) theme on jonbur groups 198 Korean stocks listed on KOSPI and KOSDAQ, worth ₩210T in total. On Oct 30, 2026 the group moved up 2.45% (weighted by market value); the largest members are Samsung Biologics, Celltrion, Alteogen.
Key facts
- Stocks
- 198
- Total market value
- ₩210T
- Day's move
- +2.45%
- As of
- Oct 30, 2026
- Largest members
- Samsung Biologics, Celltrion, Alteogen
Earnings tracker · 3Q 2026
Reporting season · reports due by Nov 14
8 of 199 reportedOperating profit up vs a year ago: 5 of 6
Revenue+22.7%
Operating profit+52.3%
Net profitTurned to profit
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Celltrion | Oct 12Preliminary | ₩1.5T | +45.8% | ₩510B | +69.2% | +12.9% | 34.0%29.3% |
| Yuhan | Oct 28Preliminary | ₩586B | +2.8% | ₩35B | +57.8% | −48.0% | 5.9%3.9% |
| Hanmi Pharm | Oct 27Preliminary | ₩377B | +4.2% | ₩38B | −31.3% | −71.2% | 10.0%15.2% |
| ST Pharm | Oct 27Preliminary | ₩98B | +19.1% | ₩16B | +6.6% | −14.3% | 16.1%18.0% |
| Bukwang Pharmaceutical IND | Oct 23Preliminary | ₩58B | +21.2% | ₩2.2B | +120.7% | +53.3% | 3.7%2.0% |
| Dong-A ST | Oct 27Preliminary | ₩207B | −4.4% | ₩21B | +52.9% | +239.9% | 10.4%6.5% |
| T&R Biofab | Oct 19Preliminary | ₩8.9B | +28.1% | — | — | — | — |
| Shaperon | Oct 1Preliminary | ₩4.7B | +2,683.4% | — | — | — | — |
| Samsung Biologics | Expected around Oct 28 | ||||||
| Hanall Biopharma | Expected around Oct 29 | ||||||
| Dong-A Pharmaceutical | Expected around Oct 29 | ||||||
| Onconic Therapeutics | Expected around Oct 30 | ||||||
| Abion | Expected around Oct 31 | ||||||
| SK Bioscience | Expected around Nov 3 | ||||||
| GC Biopharma | Expected around Nov 3 | ||||||
| Chong Kun Dang Pharmaceutical | Expected around Nov 3 | ||||||
| JW Pharmaceutical | Expected around Nov 3 | ||||||
| GC Cell | Expected around Nov 3 | ||||||
| Hyundai Bioland | Expected around Nov 3 | ||||||
| Choong ANG Vaccine Laboratory | Expected around Nov 3 | ||||||
| GC Medical Science | Expected around Nov 3 | ||||||
| Hugel | Expected around Nov 4 | ||||||
| SK biopharmaceuticals | Expected around Nov 5 | ||||||
| JW Shinyak | Expected around Nov 5 | ||||||
| IL Dong Pharmaceutical | Expected around Nov 6 | ||||||
| ISU Abxis | Expected around Nov 6 | ||||||
| Seegene | Expected around Nov 7 | ||||||
| Daewoong Pharma | Expected around Nov 7 | ||||||
| NeoImmuneTech | Expected around Nov 7 | ||||||
| QuadMedicine | Expected around Nov 7 | ||||||
| Medy-Tox | Expected around Nov 10 | ||||||
| AbClon | Expected around Nov 10 | ||||||
| Vivozon Pharmaceutical | Expected around Nov 10 | ||||||
| Eye Gene | Expected around Nov 10 | ||||||
| PharmaResearch | Expected around Nov 11 | ||||||
| ABL Bio | Expected around Nov 11 | ||||||
| Rznomics | Expected around Nov 11 | ||||||
| Pharos iBio | Expected around Nov 11 | ||||||
| J2KBIO | Expected around Nov 11 | ||||||
| Olipass | Expected around Nov 11 | ||||||
| OSCOTECInc | Expected around Nov 12 | ||||||
| MedPacto | Expected around Nov 12 | ||||||
| CTC Bio | Expected around Nov 12 | ||||||
| Gencurix | Expected around Nov 12 | ||||||
| Linkgenesis | Expected around Nov 12 | ||||||
| Chabiotech | Expected around Nov 13 | ||||||
| G2GBIO | Expected around Nov 13 | ||||||
| Pharmicell | Expected around Nov 13 | ||||||
| AprilBio | Expected around Nov 13 | ||||||
| Kangstem Biotech | Expected around Nov 13 | ||||||
| DuChemBio | Expected around Nov 13 | ||||||
| 3billion | Expected around Nov 13 | ||||||
| Genexine | Expected around Nov 13 | ||||||
| DreamCIS | Expected around Nov 13 | ||||||
| Aribiolab | Expected around Nov 13 | ||||||
| ViGenCell | Expected around Nov 13 | ||||||
| SunBio | Expected around Nov 13 | ||||||
| Pangen Biotech | Expected around Nov 13 | ||||||
| Cytogen | Expected around Nov 13 | ||||||
| KoBioLabs | Expected around Nov 13 | ||||||
| ilShinbiobase | Expected around Nov 13 | ||||||
| Aprogen Biologics | Expected around Nov 13 | ||||||
| Wonbiogen | Expected around Nov 13 | ||||||
| Eutilex | Expected around Nov 13 | ||||||
| Biotoxtech | Expected around Nov 13 | ||||||
| NGeneBio | Expected around Nov 13 | ||||||
| Alteogen | Expected around Nov 14 | ||||||
| HLB | Expected around Nov 14 | ||||||
| Peptron | Expected around Nov 14 | ||||||
| OliX Pharmaceuticals | Expected around Nov 14 | ||||||
| Voronoi | Expected around Nov 14 | ||||||
| Caregen | Expected around Nov 14 | ||||||
| Mezzion Pharma | Expected around Nov 14 | ||||||
| Naturecell | Expected around Nov 14 | ||||||
| Kolon TissueGene | Expected around Nov 14 | ||||||
| Daewoong | Expected around Nov 14 | ||||||
| JS Link | Expected around Nov 14 | ||||||
| L&C Bio | Expected around Nov 14 | ||||||
| Proteina | Expected around Nov 14 | ||||||
| Hyundai Bioscience | Expected around Nov 14 | ||||||
| Shinpoong Pharmaceutical | Expected around Nov 14 | ||||||
| GI Innovation | Expected around Nov 14 | ||||||
| GC | Expected around Nov 14 | ||||||
| HLB Life Science | Expected around Nov 14 | ||||||
| GemVax & KAEL | Expected around Nov 14 | ||||||
| Penetrium Bioscience | Expected around Nov 14 | ||||||
| Orum Therapeutics | Expected around Nov 14 | ||||||
| Medipostco | Expected around Nov 14 | ||||||
| ToolGen | Expected around Nov 14 | ||||||
| SillaJen | Expected around Nov 14 | ||||||
| NKGen Biotech Korea | Expected around Nov 14 | ||||||
| Q AID | Expected around Nov 14 | ||||||
| Genomictree | Expected around Nov 14 | ||||||
| S.Biomedics | Expected around Nov 14 | ||||||
| HLB Therapeutics | Expected around Nov 14 | ||||||
| ImmuneOncia Therapeutics | Expected around Nov 14 | ||||||
| IntoCell | Expected around Nov 14 | ||||||
| Jetema | Expected around Nov 14 | ||||||
| GC Genome | Expected around Nov 14 | ||||||
| FutureChem | Expected around Nov 14 | ||||||
| BioPlus | Expected around Nov 14 | ||||||
| Binex | Expected around Nov 14 | ||||||
| Biobijou | Expected around Nov 14 | ||||||
| Genome&Company | Expected around Nov 14 | ||||||
| Chongkundang Holdings | Expected around Nov 14 | ||||||
| curacle | Expected around Nov 14 | ||||||
| Helixmith | Expected around Nov 14 | ||||||
| Eone Diagnomics Genome Center | Expected around Nov 14 | ||||||
| Kolon Life Science | Expected around Nov 14 | ||||||
| BNC Korea | Expected around Nov 14 | ||||||
| Cellbion | Expected around Nov 14 | ||||||
| Aptabio Therapeutics | Expected around Nov 14 | ||||||
| Bio Solution | Expected around Nov 14 | ||||||
| Aribio Holdings | Expected around Nov 14 | ||||||
| Y-Biologics | Expected around Nov 14 | ||||||
| Anterogen | Expected around Nov 14 | ||||||
| TiumBio | Expected around Nov 14 | ||||||
| Celemics | Expected around Nov 14 | ||||||
| Asta | Expected around Nov 14 | ||||||
| HLB bioStep | Expected around Nov 14 | ||||||
| Aminologics | Expected around Nov 14 | ||||||
| HLB Global | Expected around Nov 14 | ||||||
| Vaxcell-Bio Therapeutics | Expected around Nov 14 | ||||||
| Corestemchemon | Expected around Nov 14 | ||||||
| iNtRON Biotechnology | Expected around Nov 14 | ||||||
| Cellumed | Expected around Nov 14 | ||||||
| Enzychem Lifesciences | Expected around Nov 14 | ||||||
| HLB Genex | Expected around Nov 14 | ||||||
| SCL Science | Expected around Nov 14 | ||||||
| Polaris AI Pharma | Expected around Nov 14 | ||||||
| Choolip & Sciences | Expected around Nov 14 | ||||||
| Sugentech | Expected around Nov 14 | ||||||
| Access Bio | Expected around Nov 14 | ||||||
| Naturalendo Tech | Expected around Nov 14 | ||||||
| Amicogen | Expected around Nov 14 | ||||||
| PharmGen Science | Expected around Nov 14 | ||||||
| Optipharm | Expected around Nov 14 | ||||||
| Adbiotech | Expected around Nov 14 | ||||||
| HLB Panagene | Expected around Nov 14 | ||||||
| Tego Science | Expected around Nov 14 | ||||||
| Cellid | Expected around Nov 14 | ||||||
| ENCell | Expected around Nov 14 | ||||||
| GeneOne Life Science | Expected around Nov 14 | ||||||
| CJ Bioscience | Expected around Nov 14 | ||||||
| Aprogen | Expected around Nov 14 | ||||||
| Geninus | Expected around Nov 14 | ||||||
| Quratis | Expected around Nov 14 | ||||||
| RPbio | Expected around Nov 14 | ||||||
| Green Lifescience | Expected around Nov 14 | ||||||
| Oncocross | Expected around Nov 14 | ||||||
| Aligned Genetics | Expected around Nov 14 | ||||||
| HLB Pep | Expected around Nov 14 | ||||||
| Kainos Medicine | Expected around Nov 14 | ||||||
| Organoidsciences | Expected around Nov 14 | ||||||
| Orientbio | Expected around Nov 14 | ||||||
| Kolmar BioTech | Expected around Nov 14 | ||||||
| IMBdx | Expected around Nov 14 | ||||||
| SeouLin Bioscience | Expected around Nov 14 | ||||||
| Genolution | Expected around Nov 14 | ||||||
| Hass | Expected around Nov 14 | ||||||
| SLSBio(Specialty Lab Solution Bio) | Expected around Nov 14 | ||||||
| Genematrix | Expected around Nov 14 | ||||||
| Synteka Bio | Expected around Nov 14 | ||||||
| C&R Research | Expected around Nov 14 | ||||||
| GFC Life Science | Expected around Nov 14 | ||||||
| Enbioco | Expected around Nov 14 | ||||||
| WooGene B&Gco | Expected around Nov 14 | ||||||
| Xcell Therapeutics | Expected around Nov 14 | ||||||
| PeopleBio | Expected around Nov 14 | ||||||
| Celestra | Expected around Nov 14 | ||||||
| ChoA Pharmaceutical | Expected around Nov 14 | ||||||
| From Bio | Expected around Nov 14 | ||||||
| BioInfra | Expected around Nov 14 | ||||||
| 208340 | Expected around Nov 14 | ||||||
| Prestige BioPharma | Expected around Nov 28 | ||||||
| HEM Pharma | Expected around Nov 28 | ||||||
| Aimed Bio | Not yet | ||||||
| Ingenia Therapeutics | Not yet | ||||||
| Samyang Biopharm | Not yet | ||||||
| Ensol Biosciences | Not yet | ||||||
| Kanaph Therapeutics | Not yet | ||||||
| Inventera | Not yet | ||||||
| Imgt | Not yet | ||||||
| HL Genomics | Not yet | ||||||
| NovMetaPharma | Not yet | ||||||
| Epi Biotech | Not yet | ||||||
| ProGen | Not yet | ||||||
| Plumbline Life Sciences | Not yet | ||||||
| Moogene Medi | Not yet | ||||||
| Invites Biocore | Not yet | ||||||
| Median Diagnostics | Not yet | ||||||
| Cronex | Not yet | ||||||
| Medizen Humancare | Not yet | ||||||
| OceansBio | Not yet | ||||||
| BioInfra Life Science | Not yet | ||||||
| 072520 | Not yet | ||||||
| 341170 | Not yet | ||||||
| 283100 | Not yet | ||||||
| 258540 | Not yet | ||||||
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 30, 2026- Above 20-day average
- 8%
- Above 60-day average
- 17.3%
- RSI above 70
- 0.6%
- RSI below 30
- 14.8%
- 52-week highs
- 0
- 52-week lows
- 27
Index gauge · Short term
Bearish
0 bullish, 2 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The Biotech (new drugs) theme covers 162 members, and only 8 percent of them sit above their 20-day average while 17.3 percent are above their 60-day average. Across the group, 0 stocks are at 52-week highs and 27 are at 52-week lows, with RSI readings running from an extreme low of 14.8 to a high of 0.6. The equal-weighted member index is labeled bearish on both the short and medium horizons, with its RSI at 32.6 and its price positioned below the cloud.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
- MaturitiesNov 1, 202685ISU Abxis: ₩50bn of bonds due in the next 6 months vs ₩23bn cash₩50bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.ISU Abxis
- MaturitiesNov 1, 202685GC Biopharma: ₩130bn of bonds due in the next 6 months vs ₩42bn cash₩130bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.GC Biopharma
- MaturitiesNov 1, 202675Hyundai Department Store: ₩200bn of bonds due in the next 6 months vs ₩158bn cash₩200bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.Hyundai Department StoreDaewonkangupHyundai G.F. HoldingsZinusHandsomeSamwonsteel
- MaturitiesNov 1, 202685SK Reit: ₩130bn of bonds due in the next 6 months vs ₩54bn cash₩350bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2025 FY.SK ReitSK hynixSK NetworksSK DiscoverySKCSK Telecom
- MaturitiesOct 29, 202675Hyundai Department Store: ₩200bn of bonds due in the next 6 months vs ₩158bn cash₩200bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.Hyundai Department StoreDaewonkangupHyundai G.F. HoldingsZinusHandsomeSamwonsteel
- MaturitiesOct 23, 202685ISU Abxis: ₩50bn of bonds due in the next 6 months vs ₩23bn cash₩50bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.ISU Abxis
ETFs for this theme
All ETFs →- UNICORN K Bio Active—0
- ACE K Bio KOSDAQ Active—0
- HANARO Bio Korea Active—0
- KODEX Bio—+₩576M
- KODEX Healthcare—−₩1.5B
- KoAct Bio Healthcare Active—0
- MIDAS Bio Healthcare Active—0
- RISE Bio TOP10 Active—0
AUM · Flow 1w
Creators talking about this
Biotech (new drugs)
−4.54%바이오 신약
The Biotech (new drugs) theme in Korea covers companies that research, develop, and commercialize novel pharmaceutical drugs, including small-molecule compounds, biologics, and next-generation therapies such as antibody and cell treatments. Korean investors often group these firms together because they share a long development timeline, heavy R&D spending, and milestones tied to clinical trials, regulatory approvals, and licensing deals with global pharmaceutical companies. The theme is distinct from generic drug manufacturers and from contract manufacturing businesses, though some companies operate in several of these areas.
198 companies · 33 up · 18 flat · 147 down
- Traded value
- ₩768B
- Value vs 20-day average
- 0.90×
- Top gainer
- Proteina +24.97%
- Largest company
- Samsung Biologics ₩69T
Companies in this theme
| Company | Price | Weekly | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
Samsung Biologics207940 · KOSPI | ₩1,487,000 | +1.43% | ₩144B | ₩69T | 6.88% |
Celltrion068270 · KOSPI | ₩191,600 | −1.44% | ₩100B | ₩44T | 7.28% |
SK biopharmaceuticals326030 · KOSPI | ₩77,700 | +1.04% | ₩12B | ₩6.1T | 6.00% |
Yuhan000100 · KOSPI | ₩75,100 | −11.33% | ₩20B | ₩5.5T | 6.83% |
Hanmi Pharm128940 · KOSPI | ₩415,000 | +14.80% | ₩103B | ₩5.3T | 9.61% |
SK Bioscience302440 · KOSPI | ₩32,750 | −1.21% | ₩2.9B | ₩2.6T | 5.50% |
Hanall Biopharma009420 · KOSPI | ₩37,500 | −6.72% | ₩5B | ₩2T | 10.56% |
GC Biopharma006280 · KOSPI | ₩130,200 | −1.51% | ₩3.2B | ₩1.5T | 6.68% |
Daewoong Pharma069620 · KOSPI | ₩101,100 | −1.27% | ₩3.1B | ₩1.2T | 10.30% |
Chong Kun Dang Pharmaceutical185750 · KOSPI | ₩63,100 | −2.47% | ₩1.5B | ₩871B | 6.34% |
Dong-A Pharmaceutical000640 · KOSPI | ₩86,900 | −3.23% | ₩493M | ₩585B | 9.45% |
GC005250 · KOSPI | ₩9,140 | −2.04% | ₩580M | ₩430B | 5.94% |
Source: KRX statistical information